- Home
- ESAB vs BIO Comparison
ESAB vs BIO Comparison
Compare ESAB & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESAB | BIO |
|---|---|---|
| Founded | 1904 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 7.1B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ESAB | BIO |
|---|---|---|
| Price | $101.19 | $287.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | $138.56 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 707.0K | 248.1K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.67 | N/A |
| Revenue | ★ $2,842,555,000.00 | N/A |
| Revenue This Year | $6.21 | $2.74 |
| Revenue Next Year | $5.33 | $3.20 |
| P/E Ratio | $28.01 | ★ $9.72 |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $89.41 | $211.43 |
| 52 Week High | $137.42 | $343.12 |
Technical Indicators
Market Signals| Indicator | ESAB | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 51.55 |
| Support Level | $97.91 | $256.85 |
| Resistance Level | $118.33 | $289.61 |
| Average True Range (ATR) | 3.82 | 8.80 |
| MACD | 0.77 | 0.17 |
| Stochastic Oscillator | 47.46 | 40.58 |
Price Performance
Historical ComparisonAbout ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.